Determination of Genetic Predisposition to Patent Ductus Arteriosus in Preterm Infants

OBJECTIVE. Patent ductus arteriosus is a common morbidity associated with preterm birth. The incidence of patent ductus arteriosus increases with decreasing gestational age to ∼70% in infants born at 25 weeks' gestation. Our major goal was to determine if genetic risk factors play a role in patent ductus arteriosus seen in preterm infants. METHODOLOGY. We investigated whether single-nucleotide polymorphisms in genes that regulate smooth muscle contraction, xenobiotic detoxification, inflammation, and other processes are markers for persistent patency of ductus arteriosus. Initially, 377 single-nucleotide polymorphisms from 130 genes of interest were evaluated in DNA samples collected from 204 infants with a gestational age of <32 weeks. A family-based association test was performed on genotyping data to evaluate overtransmission of alleles. RESULTS. P values of <.01 were detected for genetic variations found in 7 genes. This prompted additional analysis with an additional set of 162 infants, focusing on the 7 markers with initial P values of <.01, and 1 genetic variant in the angiotensin II type I receptor previously shown to be related to patent ductus arteriosus. Of the initial positive signals, single-nucleotide polymorphisms in the transcription factor AP-2 β and tumor necrosis factor receptor–associated factor 1 genes remained significant. Additional haplotype analysis revealed genetic variations in prostacyclin synthase to be associated with patent ductus arteriosus. An angiotensin II type I receptor polymorphism previously reported to be associated with patent ductus arteriosus after prophylactic indomethacin administration was not associated with the presence of a patent ductus arteriosus in our population. CONCLUSIONS. Overall, our data support a role for genetic variations in transcription factor AP-2 β, tumor necrosis factor receptor–associated factor 1, and prostacyclin synthase in the persistent patency of the ductus arteriosus seen in preterm infants.

[1]  P. Zhao,et al.  [Genetic susceptibility to retinopathy of prematurity]. , 2011, [Zhonghua yan ke za zhi] Chinese journal of ophthalmology.

[2]  M. Toet,et al.  Impact of Patent Ductus Arteriosus and Subsequent Therapy With Indomethacin on Cerebral Oxygenation in Preterm Infants , 2008, Pediatrics.

[3]  K. Johnson,et al.  Evaluation of Fetal and Maternal Genetic Variation in the Progesterone Receptor Gene for Contributions to Preterm Birth , 2007, Pediatric Research.

[4]  M. Marazita,et al.  Maternal and fetal variation in genes of cholesterol metabolism is associated with preterm delivery , 2007, Journal of Perinatology.

[5]  K. Christensen,et al.  What genome-wide association studies can do for medicine. , 2007, The New England journal of medicine.

[6]  M. Oyoshi,et al.  TRAF1 regulates recruitment of lymphocytes and, to a lesser extent, neutrophils, myeloid dendritic cells and monocytes to the lung airways following lipopolysaccharide inhalation , 2007, Immunology.

[7]  L. Ment,et al.  Genetic Susceptibility to Retinopathy of Prematurity , 2006, Pediatrics.

[8]  K. Shokat,et al.  Human Catechol-O-Methyltransferase Haplotypes Modulate Protein Expression by Altering mRNA Secondary Structure , 2006, Science.

[9]  D. Schneider,et al.  Patent Ductus Arteriosus , 2006, Circulation.

[10]  R. Clyman.  Mechanisms Regulating the Ductus Arteriosus , 2006, Neonatology.

[11]  P. Davis,et al.  Indomethacin prophylaxis, patent ductus arteriosus, and the risk of bronchopulmonary dysplasia: further analyses from the Trial of Indomethacin Prophylaxis in Preterms (TIPP). , 2006, The Journal of pediatrics.

[12]  L. Ment,et al.  Familial and Genetic Susceptibility to Major Neonatal Morbidities in Preterm Twins , 2006, Pediatrics.

[13]  Evelyn R. Hermes-DeSantis,et al.  Patent ductus arteriosus: pathophysiology and management , 2006, Journal of Perinatology.

[14]  A. Lalande,et al.  Mutations in myosin heavy chain 11 cause a syndrome associating thoracic aortic aneurysm/aortic dissection and patent ductus arteriosus , 2006, Nature Genetics.

[15]  M. State,et al.  Syndromic patent ductus arteriosus: evidence for haploinsufficient TFAP2B mutations and identification of a linked sleep disorder. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[16]  G. Robertson,et al.  A novel human homologue of Drosophila polycomblike gene is up-regulated in multiple cancers. , 2004, Gene.

[17]  B. Vásárhelyi,et al.  Angiotensin II Type 1 Receptor A1166C Polymorphism and Prophylactic Indomethacin Treatment Induced Ductus Arteriosus Closure in Very Low Birth Weight Neonates , 2003, Pediatric Research.

[18]  R. Lifton,et al.  Finding genetic contributions to sporadic disease: A recessive locus at 12q24 commonly contributes to patent ductus arteriosus , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[19]  C. Pieper,et al.  Factors influencing successful closure with indomethacin of the patent ductus arteriosus in premature infants. , 2001, Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners.

[20]  N. Laird,et al.  The family based association test method: strategies for studying general genotype–phenotype associations , 2001, European Journal of Human Genetics.

[21]  R. Buettner,et al.  Regulatory roles of AP-2 transcription factors in vertebrate development, apoptosis and cell-cycle control. , 2000, Gene.

[22]  Daniel Rabinowitz,et al.  A Unified Approach to Adjusting Association Tests for Population Admixture with Arbitrary Pedigree Structure and Arbitrary Missing Marker Information , 2000, Human Heredity.

[23]  B. Gelb,et al.  Char syndrome, an inherited disorder with patent ductus arteriosus, maps to chromosome 6p12-p21. , 1999, Circulation.

[24]  G. Leslie,et al.  Prostacyclin concentrations and transitional circulation in preterm infants requiring mechanical ventilation , 1999, Archives of disease in childhood. Fetal and neonatal edition.

[25]  A. Eidelman,et al.  Indomethacin Tocolysis Increases Postnatal Patent Ductus Arteriosus Severity , 1998, Pediatrics.

[26]  J R O'Connell,et al.  PedCheck: a program for identification of genotype incompatibilities in linkage analysis. , 1998, American journal of human genetics.

[27]  K. Zerres,et al.  Enhanced apoptotic cell death of renal epithelial cells in mice lacking transcription factor AP-2beta. , 1997, Genes & development.

[28]  J D Horbar,et al.  The Vermont-Oxford Neonatal Network: integrating research and clinical practice to improve the quality of medical care. , 1995, Seminars in perinatology.

[29]  M. Kirby,et al.  Cardiac neural crest contribution to the pulmonary artery and sixth aortic arch artery complex in chick embryos aged 6 to 18 days , 1993, The Anatomical record.

[30]  H. Ding,et al.  NF-kappaB2 mutation targets TRAF1 to induce lymphomagenesis. , 2007, Blood.

[31]  Xin Xu,et al.  Implementing a unified approach to family‐based tests of association , 2000, Genetic epidemiology.

[32]  G. E. Twente,et al.  Patent ductus arteriosus , 2013 .